Navigation Links
Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments
Date:4/29/2009

nome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

(See selected financial data on following pages.)

    HUMAN GENOME SCIENCES, INC.
    CONSOLIDATED STATEMENTS OF OPERATIONS

                                                Three Months Ended March 31,
                                                   2009             2008
                                         (dollars in thousands, except share
                                                 and per share amounts)
    Revenue:
      Product sales                             $127,769              $-
      Manufacturing and development services      29,116               -
      Research and development collaborative
       agreements                                 20,392          12,275
        Total revenue                            177,277          12,275

    Costs and expenses:
      Cost of product sales                        8,177               -
      Cost of manufacturing and development
       services                                    3,351               -
      Research and development expenses           53,675          72,691
      General and administrative expenses         14,279          16,011
        Total costs and expenses (a)              79,482          88,702
    Income (loss) from operations                 97,795         (76,427)
    Investment income                              4,296           6,707
    Interest expense                             (15,730)        (15,517)
    Gain on extinguishment of debt                38,873               -
    Gain on sale of long-term equity investment    5,259          32,518
    Other expense                                   (680)              -
    Income (loss) before taxes                   129,813         (52,719)
    Provision for inc
'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... Md. , March 25, 2015 Accelovance, ... named a finalist for "Best Contract Research Organization" at ... the World Vaccine Congress. This is ... a finalist for the award, winning for "Best Contract ... a "Highly Recommended" distinction in 2013. "We,re ...
(Date:3/25/2015)... London, UK (PRWEB) March 25, 2015 ... of natural ingredients in all forms of food nutrients, ... led to a substantial rise in demand for natural ... astaxanthin have started to ramp up their capacities to ... for both natural and synthetic source astaxanthin (used in ...
(Date:3/25/2015)... (PRWEB) March 25, 2015 Data ... Novel Mechanism of Action in Neuromuscular Diseases ... – Cytokinetics, Incorporated (Nasdaq: CYTK) announced the publication ... muscle troponin activator tirasemtiv in the journal Neurotherapeutics. ... IIa “Evidence of Effect” or hypothesis-generating clinical trial ...
(Date:3/25/2015)... Researchers at Ancon Medical Inc. ... will enable broader and less invasive screening for ... simple breath screen. The Minnesota-based medical device maker ... Drug Administration (FDA) approval process and is targeting ... Biomarker Tagging device. , Ancon Medicals nanoparticle breakthrough ...
Breaking Biology Technology:Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3
... Magellan Biosciences, a global manufacturer of products designed ... labor intensive, announced that its Vice President of Business ... featured speaker at the Medicaid Health Plans of America ... takes place tomorrow in Washington, DC. Mr. De Jesus ...
... 17, 2011 Anaphore Inc. today announced that Katherine Bowdish, ... overview at the 13th Annual C21 BioVentures conference. The presentation ... at The Meritage Resort in Napa, Calif.   ... is developing a new class of protein pharmaceuticals to address ...
... PERTH, Australia, May 17, 2011 Australian supplier of ... an exclusive distributor agreement with a leading Japanese Life ... Taiwan, China and South Korea. Headquartered in ... in the chemical, pharmaceutical and biotechnology industries and have ...
Cached Biology Technology:Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum 2Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum 3Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum 4Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum 5Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum 6Anaphore to Present Company Overview with Focus on Atrimer Technology Platform at 13th Annual C21 BioVentures Conference 2Epichem and AR Brown Sign Exclusive Distribution Agreement for Japan, Taiwan, China and South Korea 2Epichem and AR Brown Sign Exclusive Distribution Agreement for Japan, Taiwan, China and South Korea 3
(Date:3/26/2015)... 26, 2015 The Granite Club, ... and athletic club, today announced it has implemented a ... of movement for members and staff, while restricting access ... process, we selected FST,s IMID Access system because it ... our members and staff, in addition to unparalleled security," ...
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ... Biometrics - Global Strategic Business Report" report to their offering. ... Voice Biometrics in US$ Thousands by the following Segments: Face Biometrics, ... US, Canada , Japan , ... Middle East & Africa , ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... may have the potential to alleviate food insecurity ... that biotechnology has the potential to improve the ... to insects and disease. This could lead to ... and animal consumption. Researchers are also working ...
... disorder has been identified by UCL (University College London) and ... Gurling at UCL and Professor Ole Mors at the University ... in the UK and in Denmark, and then at large ... the genetic searches, published in the October issue of the ...
... is full of life--large, small, and microscopic. Bacteriophage (phage) ... material and moderate their communities through predation and parasitism. ... about as many of them in a bucket full ... As a result, they can have a huge impact ...
Cached Biology News:Are genomic technologies the answer to world hunger? 2New gene linked to bipolar disorder 2Hundreds of thousands of viral species present in the world's oceans 2
Rabbit anti-NFkB p105/p50 (Ser337) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
CD69/CD3 50 tests...
Biology Products: